Rhythm Pharmaceuticals (RYTM) Could Be 14% Undervalued Following Its CMO Appointment
Rhythm Pharmaceuticals (RYTM) stock is in focus after the company appointed Manher “AJ” Joshi, M.D., as Chief Medical Officer on 17 August 2026, adding experienced leadership in rare disease drug development.
See our latest analysis for Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals has seen momentum build over 2026, with a 30 day share price return of 8.11% and a 90 day share price return of 27.15%, while the 1 year total shareholder return of 18.58% sits against a very large 5 year total shareholder return. Recent IMCIVREE progress and leadership changes have kept the story active.
If you are looking beyond Rhythm Pharmaceuticals for other healthcare related growth stories, this could be a good moment to sift through 42 healthcare AI stocks
Rhythm Pharmaceuticals shares have already moved higher, yet there is still a wide gap between the current US$115.25 price, analyst targets and implied intrinsic value estimates. So where does fair value really sit now that expectations have shifted?
Most Popular Narrative: 14% Undervalued
Rhythm Pharmaceuticals is trading at $115.25 against a narrative fair value of $134. The gap reflects how one detailed thesis is framing IMCIVREE, the pipeline and rare disease positioning.
Rhythm Pharmaceuticals is a high-growth commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction (genetic obesity). Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio. I rate RYTM a BUY, driven by expected double-digit revenue growth, a broader targeted-obesity portfolio, and stronger-than-expected patient uptake.
The narrative from peter_4mgsy focuses on how fast rare disease revenues could scale, what long term margins might look like, and how success across several obesity indications might justify that higher fair value. Want to see which assumptions really move the $134 figure and how they stack up against Rhythm Pharmaceuticals today.
Result: Fair Value of $134 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Rhythm Pharmaceuticals still faces execution risk on IMCIVREE uptake and future trial results, which could challenge growth assumptions and put pressure on the current valuation.
Find out about the key risks to this Rhythm Pharmaceuticals narrative.
Another View: Rhythm Pharmaceuticals Through A Sales Multiple Lens
The earlier fair value narrative presents Rhythm Pharmaceuticals as undervalued at $115.25 versus $134. However, the current P/S ratio of 33.1x is well above the US Biotechs industry at 11.3x, the peer average at 9.3x, and even the estimated fair ratio of 19.7x. That gap suggests investors are already paying a premium for future growth that has not yet translated into profits. The key question is whether you think Rhythm Pharmaceuticals can grow into that premium or if expectations have moved ahead of the underlying numbers.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this Rhythm Pharmaceuticals story leaves you torn between the upside and the risks, now is the time to review the numbers yourself and act promptly. To see what current optimism is based on, take a closer look at the 3 key rewards
Looking For More Investment Ideas Beyond Rhythm Pharmaceuticals?
If Rhythm Pharmaceuticals has caught your attention, do not stop here. Use the screener to spot other stocks that match your style before the market moves.
- Target potential mispricing by reviewing companies filtered through 50 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their current metrics.
- Prioritise resilience by scanning 79 resilient stocks with low risk scores where companies show lower risk scores that may suit a steadier approach to building wealth.
- Hunt for lesser known opportunities using the screener containing 20 high quality undiscovered gems that highlight quality businesses which are not yet widely followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com